These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30817807)

  • 41. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer.
    Fisher AV; Abbott DE; Venkatesh M; Leverson GE; Campbell-Flohr SA; Ronnekleiv-Kelly SM; Greenberg CC; Winslow ER; Weber SM
    Ann Surg Oncol; 2018 Sep; 25(9):2661-2668. PubMed ID: 30003452
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
    Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
    Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
    Mirkin KA; Hollenbeak CS; Wong J
    Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant therapy for pancreatic cancer.
    Gugenheim J; Crovetto A; Petrucciani N
    Updates Surg; 2022 Feb; 74(1):35-42. PubMed ID: 34628591
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Upfront surgery vs. neoadjuvant therapy for resectable pancreatic cancer: a narrative review of available evidence.
    Ratnayake CBB; Roberts KJ; Pandanaboyana S
    Chin Clin Oncol; 2022 Feb; 11(1):2. PubMed ID: 35184565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Importance of resectability status in neoadjuvant treatment for pancreatic cancer.
    Sho M; Akahori T; Tanaka T; Kinoshita S; Nagai M; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
    J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):563-70. PubMed ID: 25921623
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis.
    da Costa WL; Tran Cao HS; Sheetz KH; Gu X; Norton EC; Massarweh NN
    Ann Surg Oncol; 2021 Jun; 28(6):3186-3195. PubMed ID: 33174146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant therapy versus upfront resection for clinically "resectable" pancreatic cancer: The debate continues.
    Sarr MG; Behrns KE
    Surgery; 2020 Dec; 168(6):993. PubMed ID: 33066983
    [No Abstract]   [Full Text] [Related]  

  • 51. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
    di Sebastiano P; Grottola T; di Mola FF
    Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis.
    Spolverato G; Vitale A; Bagante F; Connolly R; Pawlik TM
    Ann Surg; 2017 Apr; 265(4):792-799. PubMed ID: 28266967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument.
    Jayakrishnan TT; Nadeem H; Groeschl RT; George B; Thomas JP; Ritch PS; Christians KK; Tsai S; Evans DB; Pappas SG; Gamblin TC; Turaga KK
    HPB (Oxford); 2015 Feb; 17(2):131-9. PubMed ID: 25123702
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials.
    Lo W; Zureikat A
    Curr Opin Gastroenterol; 2022 Sep; 38(5):521-531. PubMed ID: 35881969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer.
    Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
    Int J Surg; 2018 Apr; 52():221-228. PubMed ID: 29425826
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neoadjuvant therapy for pancreatic cancer: Limitations and advances of response assessment (Review).
    Xu J; Zhan H; Li F; Hu S; Wang L
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.